Abstract Number: PB2309
Meeting: ISTH 2020 Congress
Background: Venous thromboembolism (VTE) patients with concomitant anemia are at increased risk for bleeding.
Aims: Compare the baseline characteristics, treatment patterns, and 24-month outcomes in patients with and without anemia (Hb < 12.0 g/dL for women, < 13.0 g/dL for men) enrolled in the Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE.
Methods: GARFIELD-VTE (ClinicalTrials.gov: NCT02155491) is a global, prospective, non-interventional study of real-world treatment practices. Of the 10,870 patients with objectively confirmed VTE enrolled between May 2014 and January 2017, 7,703 (71%) were eligible for analysis in this study.
Results: The distribution of VTE events was comparable between patients with (n=2,779) and without anemia (n=4,924) (DVT alone: 61.1% vs. 56.0%, PE ± DVT: 38.9% vs. 44.0%, respectively). Anemic patients (vs. no anemia) were more likely to be Asian (29.4% vs. 13.0%), older (59.9 years vs. 57.5 years) and have a lower BMI (27.4 kg/m2 vs. 29.1 kg/m2). Platelet counts were higher in anemic patients (267.8 109/L vs. 237.3 109/L). Several VTE risk factors were more common in anemic patients, including hospitalization (22.0% vs. 6.9%), surgery (19.2% vs. 8.2%), cancer (17.4% vs. 4.2%) and acute medical illness (8.2% vs. 4.2%). Anemic patients were more likely to be initiated on parenteral therapy alone compared with patients without anemia (26.8% vs. 11.8%), and less likely to receive a direct oral anticoagulant (38.3% vs. 53.4%). The same trends were observed at 3, 6, 12 and 24 months after VTE diagnosis (Figure 1). After 24 months of follow-up, anemic patients were at an increased risk (hazard ratio [95% confidence interval] of all-cause mortality (2.66 [2.17-3.26]) and major bleeding (3.25 [2.45-4.31). The risk of recurrent VTE was comparable between groups (Table 1).
Conclusions: VTE patients with concomitant anemia are at an increased risk of major adverse clinical outcomes.
To cite this abstract in AMA style:Goto S, Turpie AGG, Farjat AE, Weitz JI, Haas S, Ageno W, Goldhaber SZ, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, MacCallum P, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. The Influence of Anemia on Clinical Outcomes in Venous Thromboembolism: Results from GARFIELD-VTE [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/the-influence-of-anemia-on-clinical-outcomes-in-venous-thromboembolism-results-from-garfield-vte/. Accessed October 21, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-influence-of-anemia-on-clinical-outcomes-in-venous-thromboembolism-results-from-garfield-vte/